click contribut analyst contact
earn preview select biotech
earn approach provid thought select larg mid-cap biotech
compani within coverag earn preview celg
glpg th-tse updat model adjust number
price target see tabl summar chang page overal expect solid
large- mid-cap name bounc back typic reimburs
inventory-rel soft potenti sever midyear guidanc rais still
follow recent a-rel bump signific capit influx space
could see cool summer -- especi polit rhetor heat
larg cap growth headwind persist backdrop continu expect
innov smid/mid-cap compani highli special area
select under-valued larger smaller aldr compani fare best
outperform pt vs expect similar dynam biktarvi track
significantli beat consensu est vs help off-set look like potenti
weak across mani hiv atripla descovi harvoni product enabl in-lin
top line apart potenti beat truvada estimate vs like driven prep
finit exclus period see mix increasingli favor given biktarvi
best-in-class attribut help maintain share nrx essenti unchang sinc
viiv april dovato launch lt revenu revenu track toward guidanc ep
stabil continu see share trade floor valuat minim downsid risk
pipelin develop rapid filgotinib file led tgt increas bd catalyz
sector perform pt vs expect solid quarter overal particularli ms
slight tecfidera beat vs con indic resili spite
recent launch sever compet oral despit potenti spinraza miss vs
con believ lead least in-lin revenu like rais previous
conserv full-year guidanc said help reaffirm confid
commerci franchis near term longer term ms sma franchis risk remain cautiou
vumer data tecfidera ip develop addit risdiplam results/regulatori progress
on-going zolgensma launch least signific pipelin driver emerg
outperform pt weekli heplisav-b script look inflect base multipl data
sourc though captur rate variabl earli stage launch even base
conserv im sale project see high likelihood beat increas sale estimate
con prior estim importantli believ run rate
reaffirm confid heplisav long-term trajectori estimate nearli sustain out-
year annual revenu also help remov key overhang question abil
meet debt coven heplisav-b sale see signific valuat disconnect
compel buy opportun
detail celg th-tse glpg continu backpag
price prior trade day market close estimate unless otherwis note
valu usd unless otherwis note
earn preview select biotech
outperform pt vs expect anoth good quarter cf
franchis especi come inventori drawdown -- rx suggest solid
demand growth slightli higher consensu orkambi potenti enabl modest
beat sale given favor trend see possibl tweak product
sale guidanc previou though limit controversi
around long-term cf franchis opportun center debat primarili valuat
led share trade primarili broader space continu believ best-
in-class growth lack signific clinic regulatori competit ip risk high margin
warrant stock price see progress pipelin program
next month provid next potenti valu inflect
celg sector perform pt expect line quarter celg multipl myeloma
product abraxan above-consensu revenu otezla vs
con -- believ help drive slight revenu vs con
bottom-lin ep vs con beat addit help reaffirm
expect potenti valu otezla franchis possibl sale
order permit merger go forese addit hurdl
complet ftc sign-off see final step deal closur
outperform pt expect exondi gener line consensu
est note addit solidif pmo revenue/valu floor expect begin
golodirsen pdufa august nda file casimersen mid-year
progress next-gen ppmo recent move ph ii mad studi
initi data expect nonetheless expect primari focu
continu matur gene therapi platform see addit clariti
dmd gene therapi regulatori manufactur progress limb girdl type gene
therapi data low-dos cohort continu provid comfort around lt
opportun srpt full suit gene therapi asset fuel long-term share
appreci past competit dmd data overhang
sector perform pt expect gener in-lin perform top line
potenti modest jakafi beat estimate vs consensu somewhat
off-set slight miss jakavi royalti vs con howev expect good
expens control particularli follow olumi restructur could enabl
potenti bottom-lin beat mf pv growth remain solid jakafi approv acut
steroid-refractori gvhd quarter help well though beyond gvhd
see datapoint could catalyz meaning share appreci concentr
outperform pt believ quarter-over-quart lumpi like
continu variabl ex-u buy pattern though expect bounceback translarna
vs con emflaza vs con given compani
continu comfort guidanc market product like take
backseat partner pipelin asset risdiplam nda file plan key
addit type sma data expect addit proof principl data
next wave wholly-own splice modul famili dysautonomia huntington
diseas may becom avail next year like sooner mani expect expect
interest valu build
outperform pt ocaliva trx gener flat expect in-lin quarter
estim revenu pbc franchis reflect continu eu launch
momentum account improv trajectori light histor season
though note degre uptrend volum remain somewhat variabl expect focu
earn preview select biotech
continu potenti nda file adcomm launch nash ultim
address popul life cycl manag plan bezafibr addit
combos/ind could pursu continu like stock potenti
approv base long-term potenti nash opportun view street
controversi surround competit overal potenti unwarr -- light
underappreci doc enthusiasm oca reward/risk sever nash patient
high clinic bar nash
sector perform pt anticip hcv royalti base
quarterli hcv sale reflect continu market share gain mavyret
increasingli stabl price decreas ex-u wareh interestingli consensu
royalti est impli higher sale consensu project
continu believ enta hcv royalti stream continu provid
valuat floor stock reduc need dilut financ enabl stabil
potenti market volatil howev upcom readout nash potenti
hard interpret especi light market reaction mri-pdff endpoint fxr
histor mix impact view alt meaning anyway
de-risk rsv asset time away remain sector perform
th sector perform pt vs trogarzo estim revenu base
quarter prescript trend number vial distribut believ continu
reflect continu growth new patient come onto treatment perhap lower
run rate previous assum also anticip steadi momentum egrifta sale
believ could continu current trajectori ultim reach
peak long-term upsid potenti possibl ad hiv nash indic
label success life cycl extens strategi needle-fre inject launch
formul base updat sale estim assum peak trogarzo sale
pt chang
glpg sector perform pt vs take opportun updat glpg
model reflect potenti earlier launch filgotinib given week regulatori clariti
along fx updat increas pt
stat sell day vs fx eur/usd bp q-o-q unfavor usd
strength biggest potenti beat includ biktarvi con dvax heplisav-
 celg otezla biib tecfidera con vrtx orkambi
con notabl miss includ harvoni con vosevi
con descovi con atripla con spinraza
new prior estim shown incom statement follow page
price rate adjust
earn preview select biotech
earn preview select biotech
estim mm except per share item estimatesconsensu taf earn preview select biotech
adjust hiv
base rx sale
launch est
timelin
potenti
base current
million except per share antivir hcv harvoni/auth unit epclusa/auth unit unit vosevi- unit states- europe- international- total hiv genvoya unit unit unit unit unit unit descovi unit odefsey unit international- biktarvi unit antivir includ vemlidi unit product includ filgotinib prob-adjust nash asset prob-adjust yescarta total product royalti contract total revenu cost research sell gener total oper incom interest interest incom net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand
earn preview select biotech
capit market estim compani report consensu
estim mm except per share item estimatesconsensu earn preview select biotech
adjust ms revenu base im script data near- long-term
adjust out-year sma revenu reflect evolv competit dynam zolgensma po long-term
retent patient spinraza mainten
updat expens model follow announc closur nite acquisit
biogen inc million except per share rest rest rest rest zinbryta row rest probabl weight opicinumab probabl weight psp probabl weight stroke probabl weight al probabl weight al probabl weight product revenu total product total research sell gener collabor profit sharing- total oper gain sale rights- incom incom expens net net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand vertex
earn preview select biotech
estim mm except per share item estimatesconsensu cf earn preview select biotech
incorpor expens relat acquisit exon addit payment expand crsp collabor
updat po symdeko yo patient follow recent approv shift go-forward orkambi/symdeko
increment lower near-term kalydeco sale base rx data
thousand except per share symdeko tez/iva combo- product revenu revenu product oper expens incom net pre-tax incom incom attribut non-controlling interest- net incom per share outstand share outstand celgen celg
earn preview select biotech
capit market estim compani report consensu
adjust otezla abraxan pomalyst better reflect updat rx data abraxan pomalyst track slightli
prior estim
earn preview select biotech
celgen celg million except per share includ program sle net product good research sell gener total oper oper interest invest incom interest incom expens net net pre-tax incom tax net earn per share outstand share outstand sarepta
earn preview select biotech
estim mm except per share item estimatesconsensu estimatesactualnotesexondi estimate includ myonexu acquisit expens roll sarepta
adjust ex-u exondi estim better reflect potenti launch cadenc
earn preview select biotech
sarepta inc thousand except per share eu prob-adjust eu prob-adjust microdystrophin gene therapy- eu- limb girdl gene therapy- eu- research contract total good gener in-licens exondi litig licens chargestot oper incom sale intang incom chang warrant incom comprehens incom incom incom
earn preview select biotech
earn preview select biotech
incom statement thousand except share royalties- net eu royalti probability-adjust revenu probability-adjust ruxolitinib revenu probabilty-adjust revenu probability-adjust pipelin revenu prob-adjust product cost incom net pre-tax benefit incom incom per share outstand share outstand
earn preview select biotech
earn preview select biotech
increas po risdiplam given emerg data
adjust risdiplam out-year estim better reflect view potenti market share across sma type
adjust termin growth rate account addit program could add long-term valu
push back timelin treatment non-ambulatori patient translarna follow neg chmp opinion
increas probabl translarna remain eu market exist indic
inc thousand except per share net net grant good acquir intang oper incom expens incom expens incom incom incom incom gain incom intercept
earn preview select biotech
minor chang run rate base rx data oca though note track mostli in-lin est
earn preview select biotech
incom statement thousand except pbc ocaliva pbc ocaliva psc ocaliva licens total revenu cost sales- research sell gener total oper incom interest interest incom net pre-tax incom tax provision- net earn per share outstand share outstand enanta
earn preview select biotech
updat mavyret royalti estim base rx trend
earn preview select biotech
incom thousand except royalti royalti pbc nash sales- revenu good sold- gener oper incom pre-tax tax expens net incom per share outstand share outstand dilut fiscal year end appendix
earn preview select biotech
earn preview select biotech
million except per share antivir hcv harvoni/auth unit epclusa/auth unit unit vosevi- unit states- europe- international- total hiv genvoya unit unit unit unit unit unit descovi unit odefsey unit international- biktarvi unit antivir includ vemlidi unit product includ filgotinib prob-adjust nash asset prob-adjust yescarta total product royalti contract total revenu cost research sell gener total oper incom interest interest incom net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand
earn preview select biotech
million except per share antivir hcv harvoni/auth unit epclusa/auth unit unit vosevi- unit states- europe- international- total hiv genvoya unit unit unit unit unit unit descovi unit odefsey unit international- biktarvi unit antivir includ vemlidi unit product includ filgotinib prob-adjust nash asset prob-adjust yescarta total product royalti contract total revenu cost research sell gener total oper incom interest interest incom net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand earn preview select biotech
valuat risk
valuat price target deriv via dcf analysi discount rate termin growth rate
post-taf gener price target support outperform rate
risk rate price target risk includ gener hiv entrant competit hcv price pressur commerci
scientif complex cellular car-t therapi efficaci safeti risk pipelin product filgotinib
earn preview select biotech
biogen inc million except per share rest rest rest rest zinbryta row rest probabl weight opicinumab probabl weight psp probabl weight stroke probabl weight al probabl weight al probabl weight product revenu total product total research sell gener collabor profit sharing- total oper gain sale rights- incom incom expens net net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand
earn preview select biotech
biogen inc million except per share rest rest rest rest zinbryta row rest probabl weight opicinumab probabl weight psp probabl weight stroke probabl weight al probabl weight al probabl weight product revenu total product total research sell gener collabor profit sharing- total oper gain sale rights- incom incom expens net net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand earn preview select biotech
valuat risk
valuat price target deriv dcf use discount rate termin growth rate appli
follow tecfidera patent expiri valuat support sector perform rate
risk rate price target risk rate price target includ competit gener price pressur
ms competit sma
earn preview select biotech
thousand except per share symdeko tez/iva combo- product revenu revenu product oper expens incom net pre-tax incom incom attribut non-controlling interest- net incom per share outstand share outstand
earn preview select biotech
thousand except per share symdeko tez/iva combo- product revenu revenu product oper expens incom net pre-tax incom incom attribut non-controlling interest- net incom per share outstand share outstand earn preview select biotech
valuat risk
valuat price target deriv dcf analysi base busi discount rate
termin growth rate price target support outperform rate
risk rate price target risk includ lower-than-expect commerci uptak tez/iva price pressur cf
competit emerg safeti issu tripl combo
earn preview select biotech
celgen celg million except per share includ program sle net product good research sell gener total oper oper interest invest incom interest incom expens net net pre-tax incom tax net earn per share outstand share outstand celg
earn preview select biotech
celgen celg million except per share includ program sle net product good research sell gener total oper oper interest invest incom interest incom expens net net pre-tax incom tax net earn per share outstand share outstand earn preview select biotech
valuat risk
valuat price target base dcf analysi use discount rate termin growth rate beyond
revlimid cliff valuat justifi sector perform rate celg base propos acquisit
risk rate price target risk includ failur acquisit close share volatil
earn preview select biotech
sarepta inc thousand except per share eu prob-adjust eu prob-adjust microdystrophin gene therapy- eu- limb girdl gene therapy- eu- research contract total good gener in-licens exondi litig licens chargestot oper incom sale intang incom chang warrant incom comprehens incom incom incom
earn preview select biotech
sarepta inc thousand except per share eu prob-adjust eu prob-adjust microdystrophin gene therapy- eu- limb girdl gene therapy- eu- research contract total good gener in-licens exondi litig licens chargestot oper incom sale intang incom chang warrant incom comprehens incom incom incom earn preview select biotech
valuat risk
valuat price target blend dcf use discount rate termin growth rate probability-
adjust multipl adjust ep discount analys price target support outperform
risk rate price target risk includ slower-than-anticip growth commerci setback exondi
failur gain eu approv exondi failur success develop gain regulatori approv follow-on exon-
skip drug includ golodirsen casimersen clinic setback gene therapi program poor perform
confirmatori studi lead market remov increas patient discontinu
earn preview select biotech
incom statement thousand except share royalties- net eu royalti probability-adjust revenu probability-adjust ruxolitinib revenu probabilty-adjust revenu probability-adjust pipelin revenu prob-adjust product cost incom net pre-tax benefit incom incom per share outstand share outstand
earn preview select biotech
incom statement thousand except share royalties- net eu royalti probability-adjust revenu probability-adjust ruxolitinib revenu probabilty-adjust revenu probability-adjust pipelin revenu prob-adjust product cost incom net pre-tax benefit incom incom per share outstand share outstand earn preview select biotech
valuat risk
valuat price target base dcf discount futur cash flow annual termin
growth rate begin jakafi patent expiri probability-weight potenti favor strateg altern
price target support sector perform rate
risk rate price target downsid risk includ greater-than-expect slow jakafi failur extend jakafi
life cycl regulatori setback topic ruxolitinib price pressur limit efficaci signal within earlier-stag
earn preview select biotech
inc thousand except per share net net grant good acquir intang oper incom expens incom expens incom incom incom incom gain incom
earn preview select biotech
inc thousand except per share net net grant good acquir intang oper incom expens incom expens incom incom incom incom gain incom earn preview select biotech
valuat risk
valuat price target blend dcf use discount rate termin growth rate probability-adjust
multipl adjust ep discount analys price target support outperform rate
risk rate price target risk includ slower-than-expect ex-u launch translarna dmd slower-than-
anticip growth emflaza sale regulatori pushback gt-aadc neg trial result sma
earn preview select biotech
incom statement thousand except pbc ocaliva pbc ocaliva psc ocaliva licens total revenu cost sales- research sell gener total oper incom interest interest incom net pre-tax incom tax provision- net earn per share outstand share outstand
earn preview select biotech
incom statement thousand except pbc ocaliva pbc ocaliva psc ocaliva licens total revenu cost sales- research sell gener total oper incom interest interest incom net pre-tax incom tax provision- net earn per share outstand share outstand earn preview select biotech
valuat risk
valuat price target blend dcf use discount rate termin growth rate probability-
adjust multipl adjust ep discount analys price target support outperform rate
risk rate price target risk includ failur gain approv nash psc new drug-rel safeti signal
emerg unexpect increas frequenc death liver injuri signal potenti drug-rel toxic challeng
control therapeut window trial real-world set pruritu unmanag cholesterol increas stagnant
growth pbc due label chang conservat among physician uncertainti epidemiolog restrict
reimburs competit agent
earn preview select biotech
incom thousand except royalti royalti pbc nash sales- revenu good sold- gener oper incom pre-tax tax expens net incom per share outstand share outstand dilut fiscal year end
earn preview select biotech
incom thousand except royalti royalti pbc nash sales- revenu good sold- gener oper incom pre-tax tax expens net incom per share outstand share outstand dilut fiscal year end earn preview select biotech
valuat risk
valuat price target blend dcf use discount rate termin growth rate probability-
adjust multipl adjust ep discount analys valuat support sector perform
risk rate price target risk includ competit hcv nash/pbc price pressur hcv potenti
safeti signal emerg poor efficaci futur studi
earn preview select biotech
galapago glpg thousand except per share royalties/profit split fibrosi royalties- revenu sales- oper adjust short-term financi financi net pre-tax result per share outstand share outstand dilut glpg
earn preview select biotech
galapago glpg thousand except per share royalties/profit split royalties- revenu sales- oper adjust short-term financi financi net pre-tax result per share outstand share outstand dilut earn preview select biotech
valuat risk
valuat price target blend dcf use discount rate termin growth rate probability-adjust
multipl adjust ep discount analys valuat support sector perform rate
risk rate price target risk includ emerg safeti issu high regulatori bar ra drug like filgotinib
limit interpret early-stag data
earn preview select biotech
incom statement thousand except grant servic licens total revenu cost sales- research sell gener total oper incom loss interest incom incom expens net pre-tax incom tax provision- net incom earn per share outstand share outstand
earn preview select biotech
incom statement thousand except grant servic licens total revenu cost sales- research sell gener total oper incom loss interest incom incom expens net pre-tax incom tax provision- net incom earn per share outstand share outstand earn preview select biotech
valuat risk
valuat price target blend dcf use discount rate termin growth rate probability-adjust
multipl adjust ep discount analys price target support outperform rate
risk rate price target risk includ slower-than-anticip uptak heplisav-b competit prevent market
penetr uncertainti regard life cycl ultim longev
earn preview select biotech
th incom statement usd thousand royalti licens total revenu sale includ research sell gener total oper incom loss interest incom incom expens net- net pre-tax incom tax net incom earn per share outstand share outstand th-tse
earn preview select biotech
th incom statement usd thousand royalti licens total revenu sale includ research sell gener total oper incom loss interest incom incom expens net- net pre-tax incom tax net incom earn per share outstand share outstand earn preview select biotech
valuat risk
valuat price target blend dcf use discount rate termin growth rate price-to-earnings multipl
adjust ep discount analys price target support sector perform rate
risk rate price target risk includ current futur competit undefin multi-drug resist
epidemiolog non-compliance limit patent exclus egrifta manufactur capac lack long-term data
safety/efficaci regulatori uncertainti new formul addit jurisdict
earn preview select biotech
earn preview select biotech
